Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key
about
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and SpainIssues surrounding the health economic evaluation of genomic technologies.Cost-effectiveness analysis in pharmacogenomics.Pharmacogenetics education: 10 years of experience at Tel Aviv University.Are health technology assessments of pharmacogenetic tests feasible? A case study ofCYP2D6testing in the treatment of breast cancer with tamoxifenRemoving barriers to a clinical pharmacogenetics service
P2860
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2008
@uk
name
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key
@en
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key
@nl
type
label
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key
@en
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key
@nl
prefLabel
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key
@en
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key
@nl
P2860
P356
P1433
P1476
Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key
@en
P2093
Katherine Payne
P2860
P356
10.2217/14622416.9.1.1
P577
2008-01-01T00:00:00Z